According to the Zhitong Finance App, Insili Intelligence (03696.HK) announced that the first human phase I clinical trial data of ISM6331, an innovative pan-TEAD inhibitor driven by artificial intelligence, has been received by the 2026 European Society of Medical Oncology (ESMO) Annual Meeting and made a brief oral presentation (Oral Rapid Oral Presentation).

Zhitongcaijing · 4d ago
According to the Zhitong Finance App, Insili Intelligence (03696.HK) announced that the first human phase I clinical trial data of ISM6331, an innovative pan-TEAD inhibitor driven by artificial intelligence, has been received by the 2026 European Society of Medical Oncology (ESMO) Annual Meeting and made a brief oral presentation (Oral Rapid Oral Presentation).